EXECUTIVE INTERVIEWS

Guiding Bayer’s Global Innovation Engines To New Heights

A little over a year ago, Kemal Malik received some really good news — he’d been promoted. The former head of global development and chief medical officer in the pharmaceuticals division at Bayer AG had been appointed to the company’s five-member board of management. If you have ever received similar news, you probably recall the initial feeling of euphoria.

More From Executive Interviews

THE CURRENT ISSUE

  • Hiring Right Might Save Your Job
    Hiring Right Might Save Your Job

    How often have you hired the wrong person for the wrong job? If you regularly hire people, you’re likely to have missed far more than once. Painful, isn’t it? But you are not alone.

  • What Big Pharma Can Do To Combat The Latest Patent Cliff
    What Big Pharma Can Do To Combat The Latest Patent Cliff

    The patent cliff era is far from over for the pharma industry. In the last three years, some of the biggest drugmakers have seen their blockbuster patents expire, a trend that will only increase going forward. A recent study by GlobalData estimates the industry will lose more than $60 billion in revenue through the end of 2019 due to the patent cliff.

  • Diversifying Leadership Teams With People Who Have The X-Factor
    Diversifying Leadership Teams With People Who Have The X-Factor

    Workplace inequality is not a new story, particularly that of gender. During my 20 years of executive recruiting, I’ve heard almost every conceivable reason why leadership teams remain so distorted in favor of men.

  • At Navidea, A Scientific Advisory Board Points To New Directions
    At Navidea, A Scientific Advisory Board Points To New Directions

    Until recently, Navidea Biopharmaceuticals (NYSE: NAVB) described itself as a leader in precision diagnostics that identify the presence and status of diseases. It focused on the development and commercialization of precision diagnostic agents for conditions such as cancer, dementia, and movement disorders.

  • Building A Patient Advocacy, Diversity, And Engagement Focus At BMS
    Building A Patient Advocacy, Diversity, And Engagement Focus At BMS

    When Lori Abrams was named director of advocacy, diversity, and patient engagement for Global Development Operations at Bristol-Myers Squibb (BMS), she had no one to manage. In fact, her first assignment was to create the department she would oversee. “The first thing I realized was there didn’t seem to be many such departments for me to benchmark against,” she notes. “I went around to a lot of pharma companies trying to find someone to talk to, but an advocacy position focused on clinical trials just didn’t seem to exist.”

  • How BARDA Is Helping Speed Up Drug Development/Manufacture
    How BARDA Is Helping Speed Up Drug Development/Manufacture

    An unusual federal government agency, the Biomedical Advanced Research and Development Authority (BARDA), is providing funding and technical expertise to more than 85 pharmaceutical and biotech companies and 25 academic organizations.

  • Liquid Courage – Evaluating Insider Liquidity
    Liquid Courage – Evaluating Insider Liquidity

    When we meet with CEOs of emerging growth companies, there are two main concerns that keep them up at night: raising money and best positioning their business to maximize shareholder value. Most CEOs understand that their molecule is either going to work or not work; after all, biotech is a binary business.

More Magazine Articles....

LIFE SCIENCE TRAINING INSTITUTE

More From LSTI
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

VIEW THE DIGITAL EDITION

CMO SUPPLEMENT: HOW TO SELECT A CMO AND QUALIFY ITS CAPABILITIES

 UPCOMING EVENTS

Vendor Qualification and Compliance: What Sponsors & CMOs Must Know

April 21, 2015
1pm-2:30pm EDT, Online Training

INTERPHEX 2015

April 21 - 23, 2015
New York, NY

Using Social Media for Patient Recruitment in Clinical Trials

April 22, 2015
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Introductory Rate

Root Cause Analysis & CAPA Identification: A Step-by-Step Guide for Manufacturers

April 23, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

Communication With FDA: What Do We Say And How Do We Say It?

April 28, 2015
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate
See All Events